UK markets open in 6 hours 8 minutes

NIKKEI 225
38,072.23
-201.82(-0.53%)
HANG SENG
17,763.03
+16.12(+0.09%)
CRUDE OIL
79.17
+0.17(+0.22%)
GOLD FUTURES
2,334.00
+23.00(+1.00%)
DOW
37,903.29
+87.37(+0.23%)
Bitcoin GBP
46,047.95
-1,990.30(-4.14%)

Family finances

Who is the breadwinner in your family and does it matter?

Orexo AB (publ) (0H19.L)

LSE - LSE Delayed price. Currency in SEK

Add to watchlist

20.50

-0.85

(-3.98%)

At close: 05:50PM BST

Loading interactive chart…

PR Newswire
Report from Orexo AB's annual general meeting, 26 April 2024
Election of the board of directors and auditor
PR Newswire
Orexo extends patent protection for its nasal epinephrine powder product OX640 in the US
Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today announces that the United States Patent and Trademark Office (USPTO) has granted another US patent specifically related to OX640, Orexo's nasal epinephrine powder product based on the AmorphOX® drug delivery platform.
PR Newswire
Orexo announces that the condition for early redemption of its existing bonds has been fulfilled
On March 13, 2024, Orexo AB (publ), ("Orexo" or the "Company") (STO:ORX) (OTCQX:ORXOY) announced that the Company intends to redeem early the Company's existing senior unsecured bonds with maturity in February 2025 (ISIN SE0015193958) (the "Existing Bonds").